PRESS RELEASE

FOR RELEASE Friday, April 25, 2017

For more information, contact:
Tom Davis, President and CEO, arGentis Pharmaceuticals, LLC
901-881-8665

Edward Jensen, joins arGentis as Vice President, Corporate Development

Memphis, TN—arGentis™ Pharmaceuticals, LLC announced today that Edward Jensen has joined the company as Vice President, Corporate Development.

Edward has over 30 years' successful leadership and managerial experience - driving innovation, development and commercialization in diverse global, multi-national business environments and has a demonstrable track record of consistently delivering on strategic business objectives. He has substantial in-depth, broad-based, hands-on experience of most aspects of pharmaceutical drug development and commercialization, having previously held responsibilities that covered early research, manufacturing, clinical development and regulatory submissions through to product launch, making him the ideal person to assume the role of Vice President, Corporate Development for arGentis. Edward is also the interim Head of Global Project Management at Daiichi-Sankyo and has previously senior leadership positions at major pharmaceutical and life sciences companies, including Johnson & Johnson, Biogen, AstraZeneca, Blueprint, and the TransCelerate industry collaboration.

Tom Davis, CEO, stated “we are pleased that Edward has joined our team and I look forward to working with him as we continue to develop our unique treatments for autoimmune diseases”.

arGentis™ Pharmaceuticals, located in Tennessee was established to develop pharmaceuticals that address unmet medical needs. The mission of arGentis™ is to

develop and commercialize treatments to improve the health and quality of life of the targeted patient groups and provide a fair return to our investors. The current focus is on autoimmune diseases treated primarily by Rheumatologists.

arGentis™ is developing ARG201, to treat systemic scleroderma (SSc), an autoimmune disease leading to widespread collagen build up on the skin and within the vascular structures of internal organs, resulting in comorbidities such as pulmonary hypertension, kidney and gastrointestinal track failure, pulmonary fibrosis and death. SSc is an orphan disease with approximately 100,000 patients each in the U.S. and Europe. ARG201 has been granted orphan drug status in the US by the Federal Drug Administration (FDA) and in the EU by the European Medicines Agency (EMEA).

arGentis™ has a biomarker (ROT1) that indicates whether a patient will respond to treatment. If a genotype of ROT1 is present, the patient will not respond treatment. It is believed that ROT1 will also identify patients in other diseases that may respond similar treatments.

arGentis™ is also developing ARG301, utilizing an altered peptide ligand to treat rheumatoid arthritis. The first in man, Phase I clinical trial results are expected in 2017. We believe that ARG301 will be safe and effective treatment of RA with less undesirable side effects than current RA treatments.

-##-